Background
Gray font color on white background Black font color on white background White font color on black background White font color on dark blue background
Font Size

Foundation News Archive
Researchers Developing Innovative Gene Therapy for Cone-Rod Dystrophy PDF Print E-mail
In a mouse study, a Foundation-funded team at the University of Utah successfully halted retinal degeneration.
Read more...
 
VisionWalk: $30 Million and Counting PDF Print E-mail
Launched eight years ago, the Foundation’s 5K fundraising program reaches a hard-earned milestone while it continues to gain strength.
Read more...
 
Drug Restores Vision in Retina without Functional Photoreceptors PDF Print E-mail
Successful in a mouse model, the Foundation-funded treatment shows promise for eventually working in humans.
Read more...
 
Companies Collaborate to Advance Dominant RP Gene Therapy PDF Print E-mail
The American and Irish outfits have teamed up to increase the treatment’s chances of making it to the marketplace.
Read more...
 
Second Sight Reports Future Plans for Bionic Retinas PDF Print E-mail
Its Argus II system will be tested for use in patients with dry AMD and upgraded to provide more detailed vision.
Read more...
 
ProgSTAR Study to Include Patients with Rare Form of Stargardt Disease PDF Print E-mail
With help from the Shulsky Foundation, FFB’s Clinical Research Institute expands the breadth of its investigation.
Read more...
 
Vision-Saving Research Highlighted at Foundation’s Orange County Symposium PDF Print E-mail

The event also focused on ways in which academics, venture capitalists and companies are collaborating to offer treatments for retinal diseases.

Read more...
 
Thyroid Hormone Suppression — An Emerging Approach for Saving Vision PDF Print E-mail
A recent study shows that the therapy, which still needs to be tailored to humans, could be used to treat a number of retinal diseases.
Read more...
 
Sanofi to Lead Commercialization of Two Retinal Disease Gene Therapies PDF Print E-mail

The treatments, developed by the company Oxford BioMedica, target specific forms of Stargardt disease and Usher syndrome.

Read more...
 
Aerobic Exercise Preserves Vision in Retinal Degeneration Lab Study PDF Print E-mail
Researchers are hopeful that the low-cost, non-invasive intervention will prove effective in humans as well.
Read more...
 
Synthetic Form of Active Marijuana Ingredient Preserves Vision in Rats with RP PDF Print E-mail
The treatment has also produced positive results in other disease studies, but would need to be refined before it’s tested in humans.
Read more...
 
Consortium to Genetically Screen All Israelis with Inherited Retinal Diseases PDF Print E-mail
The potential benefits of the Foundation-funded project, involving an estimated 5,000 people, include discovering disease-causing genes and recruiting clinical trial participants.
Read more...
 
U.K. Company Receives $16 Million to Advance Choroideremia Gene Therapy PDF Print E-mail
Called Nightstar, the company will eventually provide commercial support for treatments targeting a variety of diseases.
Read more...
 
First Patients Receive Commercial Implant of Argus II Bionic Retina PDF Print E-mail
The device, which received FDA approval last year, is able to restore limited vision to people with advanced RP.
Read more...
 
Vision-Saving Benefits of Lucentis Lessen Over Time for Some Patients PDF Print E-mail
A study funded by the drug’s producer shows that one-third of its participants lost three or more lines of vision when reading an eye chart.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 Next > End >>

Page 1 of 6
US Images

Chapters

Select a state from the dropdown below to view local chapters.


Free Information

Register here to receive free information about your eye condition and research efforts to find treatments and cures.

VISIONS 2014 banner
2013 Annual Report banner
VisionWalk banner